AI-enabled prescription digital therapeutics (PDTs) are emerging as a transformative force, offering personalized and adaptive treatment journeys that enhance patient outcomes. Unlike traditional AI applications that address existing challenges, these advanced PDTs create new avenues for value creation by building dynamic relationships with patients and providing novel clinical insights. In this article for MedCity News, David Benshoof Klein, Founder & CEO of Click Therapeutics, shares how investors seeking substantial growth opportunities should focus on companies leveraging AI in this innovative manner, as they are poised to revolutionize the treatment paradigm. To learn more, you can read the full article in MedCity News.